Barington Takes $5.56M Position in Chemed as Stock Slides 15% YoY

The Motley FoolThe Motley Fool
|||1 min read
Key Takeaway

Barington Companies buys $5.56M stake in Chemed as stock drops 15% YoY, viewing depressed valuation as opportunity in healthcare-services company.

Barington Takes $5.56M Position in Chemed as Stock Slides 15% YoY

Barington Companies Management has initiated a new position in Chemed Corporation, purchasing 13,000 shares valued at $5.56 million, which represents 3.65% of the investment firm's reportable assets. The stake establishment comes as Chemed's stock has declined 15.18% over the past twelve months, suggesting the institutional investor views current valuation levels as an opportunity to gain exposure to the diversified healthcare and services company.

Chemed operates two primary business divisions: VITAS, a leading provider of hospice and palliative care services, and Roto-Rooter, which offers residential and commercial plumbing services. The company has maintained a strong balance sheet and consistent cash generation capabilities, though recent margin pressures have weighed on operational performance and contributed to the stock's underperformance relative to broader market indices.

Barington's investment reflects a contrarian positioning in a company whose defensive business characteristics—particularly in essential services like hospice care and emergency plumbing—typically insulate it from broader economic cycles. The firm's decision to establish a material position suggests management believes the current market discount adequately compensates for near-term operational headwinds.

Source: The Motley Fool

Back to newsPublished Feb 16

Related Coverage

GlobeNewswire Inc.

Corcept Therapeutics Faces Class Action Over FDA Rejection; Stock Crashed 50%

Corcept Therapeutics faces securities fraud lawsuit after FDA rejected relacorilant application. Stock plummeted 50.4% following December rejection. Investor deadline April 21, 2026.

CORT
Investing.com

D-Wave's 44% Plunge Masks Quantum Leap: Growth Story vs. Valuation Reality

D-Wave ($QBTS) fell 44% in 2026 despite strong bookings exceeding 2025 totals and $30M in major deals. Analysts see 132% upside, but 237x sales valuation remains extreme.

QBTS
GlobeNewswire Inc.

OneMain Holdings Faces Multi-State Securities Probe Over Alleged Lending Fraud

Pomerantz Law Firm investigates $OMF following multi-state lawsuit alleging deceptive lending practices. Stock tumbles 5.38% on fraud allegations.

OMF
Investing.com

Chipotle's Menu Comeback Sparks Analyst Upgrades as Turnaround Gains Momentum

Chipotle rebounds with Chicken al Pastor relaunch boosting Q1 traffic. Multiple analyst upgrades target 50% upside; activist Dan Loeb's Third Point takes position.

CMG
GlobeNewswire Inc.

Boston Scientific Faces Securities Fraud Lawsuit Over Overstated EP Growth Claims

Boston Scientific faces class action lawsuit alleging material misstatements about electrophysiology growth. Stock fell 17.6% after disclosing slower market growth and competitive pressures.

BSX
GlobeNewswire Inc.

Nektar Therapeutics Faces Class Action Over Failed Trial Data Disclosure

Pomerantz LLP filed securities fraud class action against Nektar Therapeutics, alleging false statements about clinical trial enrollment procedures led to trial failure and stock decline.

NKTR